Google Übersetzer
Corcept Therapeutics Incorporated
About
Corcept Therapeutics Incorporated — investor relations, events, news, and company updates on 6ix.
Latest News
Apr 30 2026
Corcept Phase 2 Study of Dazucorilant Demonstrates Two-Year Overall Survival Benefit in Patients with Amyotrophic Lateral Sclerosis
Apr 21 2026
Corcept to Present New Data from Pivotal Phase 3 ROSELLA Trial of Lifyorli™ (Relacorilant) in Patients with Platinum-Resistant Ovarian Cancer at ASCO 2026
Apr 10 2026
Corcept Presents Complete Data from Pivotal ROSELLA Trial in SGO Late-Breaker with Simultaneous Publication in The Lancet: Lifyorli™ (Relacorilant) Plus Nab-Paclitaxel Improves Overall Survival in Patients with Platinum-Resistant Ovarian Cancer
Mar 28 2026
Corcept Presents Data from MOMENTUM Trial at American College of Cardiology Annual Scientific Session
Mar 26 2026
Onco360® Has Been Selected as the National Pharmacy Partner for LIFYORLI™ (relacorilant)